McKesson Co. (NYSE:MCK) EVP Thomas L. Rodgers sold 198 shares of McKesson stock in a transaction on Tuesday, June 8th. The shares were sold at an average price of $192.85, for a total value of $38,184.30. Following the transaction, the executive vice president now owns 1,161 shares in the company, valued at approximately $223,898.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Thomas L. Rodgers also recently made the following trade(s):
- On Tuesday, June 1st, Thomas L. Rodgers sold 145 shares of McKesson stock. The shares were sold at an average price of $189.56, for a total value of $27,486.20.
NYSE MCK opened at $195.51 on Friday. McKesson Co. has a twelve month low of $139.76 and a twelve month high of $204.66. The company has a quick ratio of 0.59, a current ratio of 1.03 and a debt-to-equity ratio of 82.70. The firm has a market cap of $30.93 billion, a PE ratio of -6.83, a PEG ratio of 1.47 and a beta of 0.88. The business’s 50-day simple moving average is $193.79.
The company also recently declared a quarterly dividend, which will be paid on Thursday, July 1st. Shareholders of record on Tuesday, June 1st will be issued a $0.42 dividend. The ex-dividend date is Monday, May 31st. This represents a $1.68 annualized dividend and a yield of 0.86%. McKesson’s dividend payout ratio (DPR) is 9.76%.
A number of institutional investors have recently bought and sold shares of MCK. Illinois Municipal Retirement Fund raised its holdings in shares of McKesson by 686.0% in the 4th quarter. Illinois Municipal Retirement Fund now owns 42,429 shares of the company’s stock worth $7,379,000 after buying an additional 37,031 shares in the last quarter. KCS Wealth Advisory raised its holdings in shares of McKesson by 14.5% in the 1st quarter. KCS Wealth Advisory now owns 6,891 shares of the company’s stock worth $1,344,000 after buying an additional 874 shares in the last quarter. Leuthold Group LLC raised its holdings in shares of McKesson by 734.1% in the 4th quarter. Leuthold Group LLC now owns 16,606 shares of the company’s stock worth $2,888,000 after buying an additional 14,615 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of McKesson by 15.9% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 56,845 shares of the company’s stock worth $11,087,000 after buying an additional 7,811 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC raised its holdings in shares of McKesson by 1.0% in the 4th quarter. Quantitative Systematic Strategies LLC now owns 20,821 shares of the company’s stock worth $3,621,000 after buying an additional 211 shares in the last quarter. 85.34% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have recently weighed in on the company. Mizuho lifted their price target on McKesson from $190.00 to $205.00 and gave the company a “neutral” rating in a report on Wednesday, May 12th. Credit Suisse Group lifted their price target on McKesson from $192.00 to $222.00 and gave the company a “neutral” rating in a report on Monday, May 10th. Argus upgraded McKesson from a “hold” rating to a “buy” rating and set a $230.00 price target on the stock in a report on Tuesday, March 30th. Cowen lifted their price target on McKesson from $210.00 to $224.00 and gave the company an “outperform” rating in a report on Tuesday, March 2nd. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on McKesson from $231.00 to $237.00 and gave the company a “buy” rating in a report on Friday, May 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $209.18.
McKesson Company Profile
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).
Further Reading: Why is the price-sales ratio important?
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.